Richard Kim, MD, FRCPC
SPECIALTY AND TITLE
Clinical Pharmacology, Professor
London Health Sciences Centre
AREA OF RESEARCH
Drug Metabolism and Transport
MAJOR CONTRIBUTIONS TO SCIENCE AND/OR HEALTH CARE DELIVER
In 2008, we established Canada’s first Personalized Medicine Clinic here at London Health Sciences Centre, and we have become well known locally, regionally, nationally, and internationally, for providing pharmacogenomic-based personalized medicine to our patients. As a part of our program, we have enrolled a large cohort of patients with inflammatory bowel disease (IBD), to aid in the selection of safe and effective IBD therapies. A tangible example of our success in translation of pharmacogenomics to patient care is demonstrated by the approval of pre-treatment DPYD genotype testing prior to 5-fluorouracil or capecitabine chemotherapies in April 2023 by the Ontario Ministry of Health.